Cybin (CYBN) Competitors $11.00 +0.50 (+4.76%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CYBN vs. IMNM, IGMS, CRON, ANNX, TRDA, TRML, STOK, ORIC, NUVB, and ABUSShould you be buying Cybin stock or one of its competitors? The main competitors of Cybin include Immunome (IMNM), IGM Biosciences (IGMS), Cronos Group (CRON), Annexon (ANNX), Entrada Therapeutics (TRDA), Tourmaline Bio (TRML), Stoke Therapeutics (STOK), ORIC Pharmaceuticals (ORIC), Nuvation Bio (NUVB), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. Cybin vs. Immunome IGM Biosciences Cronos Group Annexon Entrada Therapeutics Tourmaline Bio Stoke Therapeutics ORIC Pharmaceuticals Nuvation Bio Arbutus Biopharma Immunome (NASDAQ:IMNM) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking. Does the MarketBeat Community favor IMNM or CYBN? Immunome received 20 more outperform votes than Cybin when rated by MarketBeat users. However, 100.00% of users gave Cybin an outperform vote while only 73.81% of users gave Immunome an outperform vote. CompanyUnderperformOutperformImmunomeOutperform Votes3173.81% Underperform Votes1126.19% CybinOutperform Votes11100.00% Underperform VotesNo Votes Do analysts rate IMNM or CYBN? Immunome currently has a consensus price target of $28.83, suggesting a potential upside of 158.83%. Cybin has a consensus price target of $45.50, suggesting a potential upside of 313.64%. Given Cybin's higher probable upside, analysts plainly believe Cybin is more favorable than Immunome.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer IMNM or CYBN? In the previous week, Immunome had 3 more articles in the media than Cybin. MarketBeat recorded 12 mentions for Immunome and 9 mentions for Cybin. Cybin's average media sentiment score of 0.17 beat Immunome's score of 0.10 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Is IMNM or CYBN more profitable? Cybin has a net margin of 0.00% compared to Immunome's net margin of -2,435.02%. Immunome's return on equity of -38.19% beat Cybin's return on equity.Company Net Margins Return on Equity Return on Assets Immunome-2,435.02% -38.19% -29.63% Cybin N/A -42.36%-40.56% Which has more volatility & risk, IMNM or CYBN? Immunome has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, Cybin has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Do insiders and institutionals have more ownership in IMNM or CYBN? 44.6% of Immunome shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 8.6% of Immunome shares are held by insiders. Comparatively, 15.0% of Cybin shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation and earnings, IMNM or CYBN? Cybin has lower revenue, but higher earnings than Immunome. Cybin is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunome$14.02M47.71-$106.81M-$7.69-1.45CybinN/AN/A-$57.88M-$6.08-1.81 SummaryImmunome beats Cybin on 9 of the 16 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYBN vs. The Competition Export to ExcelMetricCybinPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$219.89M$7.05B$5.41B$19.78BDividend YieldN/A8.03%5.01%3.50%P/E Ratio-1.8111.53124.8544.86Price / SalesN/A348.331,252.5318.00Price / CashN/A49.2239.8421.68Price / Book1.029.086.314.68Net Income-$57.88M$154.47M$119.66M$982.42M7 Day Performance1.95%-2.36%-1.26%-1.39%1 Month Performance13.40%3.10%2.23%1.42%1 Year PerformanceN/A36.17%35.76%24.78% Cybin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYBNCybin1.6849 of 5 stars$11.00+4.8%$45.50+313.6%N/A$219.89MN/A-1.8150Analyst ForecastNews CoveragePositive NewsHigh Trading VolumeIMNMImmunome1.8604 of 5 stars$12.98+3.5%N/A+38.9%$779.45M$14.02M-1.6940Analyst ForecastNews CoverageIGMSIGM Biosciences4.6264 of 5 stars$13.03-9.3%N/A+108.7%$772.93M$2.91M-3.55190Earnings ReportAnalyst ForecastShort Interest ↓High Trading VolumeCRONCronos Group2.0299 of 5 stars$2.00-2.9%N/A+3.5%$764.59M$87.24M-13.33356Short Interest ↓Analyst RevisionNews CoverageANNXAnnexon2.6823 of 5 stars$7.23-1.8%N/A+155.2%$763.88MN/A-5.8860Short Interest ↓TRDAEntrada Therapeutics2.5592 of 5 stars$19.82+3.1%N/A+13.1%$741.66M$129.01M12.47110Insider SellingHigh Trading VolumeTRMLTourmaline Bio2.7372 of 5 stars$28.76+4.0%N/A+63.7%$737.44MN/A-10.2044Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageSTOKStoke Therapeutics3.9263 of 5 stars$13.88+4.6%N/A+195.5%$735.18M$8.78M-6.61100Positive NewsORICORIC Pharmaceuticals4.2698 of 5 stars$10.26+3.1%N/A+30.2%$723.74MN/A-5.8680Earnings ReportAnalyst ForecastNews CoverageNUVBNuvation Bio2.3372 of 5 stars$2.88+9.9%N/A+115.4%$717.81MN/A-1.3360Gap UpHigh Trading VolumeABUSArbutus Biopharma2.8369 of 5 stars$3.75+0.5%N/A+93.1%$710.60M$18.14M-8.7273Short Interest ↓ Related Companies and Tools Related Companies IMNM Competitors IGMS Competitors CRON Competitors ANNX Competitors TRDA Competitors TRML Competitors STOK Competitors ORIC Competitors NUVB Competitors ABUS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CYBN) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your fi...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
